<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.91007</article-id><article-id pub-id-type="publisher-id">ACM-28547</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190100000_22567121.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  SHR-1210对食管癌术后患者心脏功能的影响
  Effect of SHR-1210 on Cardiac Function in Patients after Esophageal Cancer Operation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孟</surname><given-names>庆国</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>佳雪</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>斯佳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>四川省广元市第二人民医院特检科，四川 广元</addr-line></aff><aff id="aff2"><addr-line>四川省医学科学院·四川省人民医院，四川 成都</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>33</fpage><lpage>36</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：应用组织多普勒技术(Tissue Doppler Imaging, TDI)对服用SHR-1210治疗的食管癌术后双心室功能回顾比较，探讨术后2年期使用该类药物对心脏功能的影响。方法：比对42例食管癌术后患者使用该类药物前、后二尖瓣侧壁瓣环、间隔瓣环及右室侧壁瓣环舒张期运动速度，右室侧壁瓣环M型运动幅度以及左心室射血分数。结果：服用药物前后左心室二尖瓣侧壁瓣环、间隔瓣环及右室侧壁瓣环舒张期运动速度均明显减低(P &lt; 0.05)；左心室、右心室收缩功能无明显变化(P &gt; 0.05)。结论：服用SHR-1210两年治疗期的食管癌患者左心室、右心室收缩功能无明显变化，但双心室舒张功能均明显降低，提示该类药物可能损害心肌功能。
    Objective: To evaluate the effect of two-year postoperative 2-week period on the function of patients with esophageal cancer treated with SHR-1210 using tissue Doppler imaging (TDI) technique. Methods: the levee anterior and posterior mitral valve sidewall annulus, spacer annulus and right ventricular sidewall anastomosis, Right ventricular sidewall annulus M-type motion Amplitude and left ventricular ejection fraction of 42 patients with esophageal cancer after operation were compared. Results: The left ventricular mitral valve valvular annulus, septum annulus and right ventricular wall anastomosis were significantly decreased before and after taking the drug (P &lt; 0.05). There was no significant change in left ventricular and right ventricular systolic function (P &gt; 0.05). Conclusion: There is no significant change in left ventricular and right ventricular systolic function in patients with esophageal cancer who have been treated with SHR-1210 for two years, but the diastolic function of both ventricles is significantly reduced, suggesting that this drug may impair myocardial function. 
  
 
</p></abstract><kwd-group><kwd>超声心动描记术，食管癌，心室，功能, Echocardiography</kwd><kwd> Esophageal Cancer</kwd><kwd> Ventricle</kwd><kwd> Function</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>SHR-1210对食管癌术后患者心脏功能的影响<sup> </sup></title><p>孟庆国<sup>1</sup>，王佳雪<sup>2</sup>，王斯佳<sup>1</sup></p><p><sup>1</sup>四川省医学科学院•四川省人民医院，四川 成都</p><p><sup>2</sup>四川省广元市第二人民医院特检科，四川 广元</p><p><img src="//html.hanspub.org/file/7-1570735x1_hanspub.png" /></p><p>收稿日期：2018年12月24日；录用日期：2019年1月14日；发布日期：2019年1月21日</p><disp-formula id="hanspub.28547-formula65"><graphic xlink:href="//html.hanspub.org/file/7-1570735x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：应用组织多普勒技术(Tissue Doppler Imaging, TDI)对服用SHR-1210治疗的食管癌术后双心室功能回顾比较，探讨术后2年期使用该类药物对心脏功能的影响。方法：比对42例食管癌术后患者使用该类药物前、后二尖瓣侧壁瓣环、间隔瓣环及右室侧壁瓣环舒张期运动速度，右室侧壁瓣环M型运动幅度以及左心室射血分数。结果：服用药物前后左心室二尖瓣侧壁瓣环、间隔瓣环及右室侧壁瓣环舒张期运动速度均明显减低(P &lt; 0.05)；左心室、右心室收缩功能无明显变化(P &gt; 0.05)。结论：服用SHR-1210两年治疗期的食管癌患者左心室、右心室收缩功能无明显变化，但双心室舒张功能均明显降低，提示该类药物可能损害心肌功能。</p><p>关键词 :超声心动描记术，食管癌，心室，功能</p><disp-formula id="hanspub.28547-formula66"><graphic xlink:href="//html.hanspub.org/file/7-1570735x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-1570735x7_hanspub.png" /> <img src="//html.hanspub.org/file/7-1570735x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>目前，随着肿瘤患者的日益增多和年轻化，食管癌当发现的时候多为中晚期，只有50%左右的患者有机会接受手术治疗 [<xref ref-type="bibr" rid="hanspub.28547-ref1">1</xref>] 。辅助化疗药物能有效减小肿瘤体积，降低肿瘤分期，给不能手术的食管癌患者带来手术机会，但也可能对患者的脏器功能产生负面影响。国内外很多学者开始关注化疗药物对心脏功能的影响 [<xref ref-type="bibr" rid="hanspub.28547-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.28547-ref3">3</xref>] 。为了探讨SHR-1210是否同样存在这样的影响，本研究通过TDI技术评估使用该类药物后患者心脏功能的变化。</p></sec><sec id="s4"><title>2. 一般资料</title><sec id="s4_1"><title>2.1. 研究对象</title><p>对比分析2013年2月~2018年6月我院接受SHR-1210治疗的42例食管癌患者，年龄31~55岁，平均32.67 &#177; 11.12岁，治疗前均通过心脏超声、心电图和常规生化检查为(−)；我院体检中心筛查40例健康对照组，年龄30~56岁，平均33.36 &#177; 12.45岁，心脏超声、心电图及常规生化检查均(−)。纳入标准：药物治疗前临床检查及病史排除合并高血压、糖尿病和肾脏疾病，心脏超声检查心脏功能正常食管癌患者。</p></sec><sec id="s4_2"><title>2.2. 仪器与方法</title><p>采用GE E9心脏彩超仪，探头Ms5 (频率1.7~3.4 MHz)，在机获取二尖瓣环及三尖瓣环组织多普勒速度参数以及三尖瓣环最大位移。</p></sec><sec id="s4_3"><title>2.3. 统计学方法</title><p>应用SPSS 16.0分析软件，所有参数满足正态分布以均数 + 标准差表示，组间比较进行t检验，治疗前后采用配对t检验，均以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>服用药物前后左心室二尖瓣侧壁瓣环、间隔瓣环及右室侧壁瓣环舒张期运动速度均明显减低(P &lt; 0.05)见表1；左心室、右心室收缩功能无明显变化(P &gt; 0.05)，见表2。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The parameters of left ventricle before and after treatment were compared with those of control group ( x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >二尖瓣</th><th align="center" valign="middle"  colspan="3"  >二尖瓣环</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >E峰(cm/s)</td><td align="center" valign="middle" >A峰(cm/s)</td><td align="center" valign="middle" >e'(cm/s)</td><td align="center" valign="middle" >a'(cm/s)</td><td align="center" valign="middle" >E/e'</td><td align="center" valign="middle" >LVEF (%)</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >1.21 &#177; 0.13<sup>*</sup></td><td align="center" valign="middle" >0.68 &#177; 0.14<sup>*</sup></td><td align="center" valign="middle" >0.19 &#177; 0.05<sup>*</sup></td><td align="center" valign="middle" >0.14 &#177; 0.04<sup>*</sup></td><td align="center" valign="middle" >3 &#177; 2<sup>*</sup></td><td align="center" valign="middle" >72 &#177; 6</td></tr><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >1.13 &#177; 0.20<sup>#</sup></td><td align="center" valign="middle" >0.57 &#177; 0.11<sup>#</sup></td><td align="center" valign="middle" >0.18 &#177; 0.04<sup>#</sup></td><td align="center" valign="middle" >0.15 &#177; 0.04<sup>#</sup></td><td align="center" valign="middle" >5 &#177; 2<sup>#</sup></td><td align="center" valign="middle" >73 &#177; 6</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >0.59 &#177; 0.16<sup>*#</sup></td><td align="center" valign="middle" >1.27 &#177; 0.17<sup>*#</sup></td><td align="center" valign="middle" >0.10 &#177; 0.03<sup>*#</sup></td><td align="center" valign="middle" >0.16 &#177; 0.03<sup>*</sup></td><td align="center" valign="middle" >11 &#177; 2<sup>*#</sup></td><td align="center" valign="middle" >68 &#177; 6</td></tr></tbody></table></table-wrap><p>表1. 治疗前后左心室各参数与对照组比较( x &#175; &#177; s)</p><p>注：与对照组比较<sup>*</sup>P &lt; 0.05，治疗前后比较，<sup>#</sup>P &lt; 0.05。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The parameters of right ventricle before and after treatment were compared with those of control group ( x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >三尖瓣</th><th align="center" valign="middle"  colspan="2"  >三尖瓣环</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >E峰(cm/s)</td><td align="center" valign="middle" >A峰(cm/s)</td><td align="center" valign="middle" >e'</td><td align="center" valign="middle" >a'</td><td align="center" valign="middle" >TAPsE (mm)</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >0.94 &#177; 0.15</td><td align="center" valign="middle" >0.74 &#177; 0.09</td><td align="center" valign="middle" >0.20 &#177; 0.06</td><td align="center" valign="middle" >0.13 &#177; 0.03</td><td align="center" valign="middle" >2.58 &#177; 0.38</td></tr><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >0.87 &#177; 0.22</td><td align="center" valign="middle" >0.67 &#177; 0.18</td><td align="center" valign="middle" >0.18 &#177; 0.04</td><td align="center" valign="middle" >0.14 &#177; 0.05</td><td align="center" valign="middle" >2.46 &#177; 0.50</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >0.54 &#177; 0.16</td><td align="center" valign="middle" >0.87 &#177; 0.10</td><td align="center" valign="middle" >0.10 &#177; 0.03</td><td align="center" valign="middle" >0.19 &#177; 0.04</td><td align="center" valign="middle" >2.37 &#177; 0.43</td></tr></tbody></table></table-wrap><p>表2. 治疗前后右心室功能与对照组比较( x &#175; &#177; s)</p><p>注：与对照组比较<sup>*</sup>P &lt; 0.05，治疗前后比较，<sup>#</sup>P &lt; 0.05，TAPsE：三尖瓣侧壁瓣环位移。</p></sec><sec id="s6"><title>4. 讨论</title><p>目前有研究表明化疗药物可引起心脏损伤，例如蒽环类药物存在心脏毒性，可以引起心力衰竭、心肌缺血、心律失常等 [<xref ref-type="bibr" rid="hanspub.28547-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.28547-ref5">5</xref>] 。近年来，程序性死亡受体(Programmed Celldeath-1 Protein, PD-1)及其配体 PD-L1的单克隆抗体治疗多种恶性肿瘤的临床研究 [<xref ref-type="bibr" rid="hanspub.28547-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.28547-ref7">7</xref>] 相继获得成功，先后获得美国食品药品管理局(FDA)批准用于恶性黑色素瘤、非小细胞肺癌、尿路上皮癌及Merkel细胞癌等15种实体瘤。但是，长期服用该药是否存在对心肌功能的损害，目前对化学治疗药物的心脏毒性的评价尚缺乏统一、高效的监测指标。故本研究采用斑点追踪技术及临床应用最为广泛的组织多普勒技术联合评估心肌功能，旨在为临床药物治疗提供参考指标。</p><p>应变和应变率成像作为早期检查左室功能障碍的有效方法，这些方法可能在未来既能评估，也能监测癌症患者的心脏功能 [<xref ref-type="bibr" rid="hanspub.28547-ref8">8</xref>] 。有研究表明 [<xref ref-type="bibr" rid="hanspub.28547-ref9">9</xref>] ，剂量累积是心脏毒性发生的独立高危因素。本研究发现，所有完成随访的食管癌患者经过2年的药物治疗后，超声心动图检查提示双室舒张功能均减低，且差异有统计学意义；而患者的双室收缩功能在治疗前后均未见明显改变。说明化疗药物对心肌功能的损伤可能最先表现为心室舒张功能上的改变，在患者未出现相关临床症状时即可发现，但需要临床密切随访、复查。传统的监测指标为左心射血分数，LVEF相比，心肌应变和应变率成像是检测心脏毒性的较敏感的方法，因为它能够提供心肌力学的多维度评估(纵向、径向和环向应变)，在LVEF还没有降低时，就能够发现局部室壁运动异常 [<xref ref-type="bibr" rid="hanspub.28547-ref10">10</xref>] 。而本研究中显示：在左室、右室收缩功能正常情况下，左心室的整体应变值明显降低，右心室的舒张功能也减低。说明传统单一的监测指标不能真实反映患者心脏功能的改变，应该采用更敏感的技术指标综合评估心肌功能，为临床提供更准确、及时信息。</p><p>目前在国内，心电图仍为检测恶性肿瘤治疗后心脏损伤的常用诊断措施之一。超声心动图不仅能测量心脏内部血流动力学、心脏结构等，而且通过一些新技术手段还可以早期发现化疗药物对心肌毒性损伤，诸如本研究中的组织斑点跟踪显像技术，对于化疗早期心肌功能的隐匿性改变均可以提供一些敏感指标。</p><p>研究不足之处：回顾性分析病例，超声图像由不同超声医师获得，存在一定程度的差异性。</p></sec><sec id="s7"><title>5. 结语</title><p>总之，本研究认为对于食管癌患者应该密切随访，并建议采用更新更敏感超声技术进行系统评估，早期发现患者心功能改变，提高患者生存率。</p></sec><sec id="s8"><title>文章引用</title><p>孟庆国,王佳雪,王斯佳. SHR-1210对食管癌术后患者心脏功能的影响Effect of SHR-1210 on Cardiac Function in Patients after Esophageal Cancer Operation[J]. 临床医学进展, 2019, 09(01): 33-36. https://doi.org/10.12677/ACM.2019.91007</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28547-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">van Hagen, P. (2012) Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. New England Journal of Medicine, 366, 2074-2084. &lt;br&gt;https://doi.org/10.1056/NEJMoa1112088</mixed-citation></ref><ref id="hanspub.28547-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">胡月珍. 曲妥珠单抗与蒽环类药物不同联合治疗方案对乳腺癌的疗效及患者心脏功能的影响[J]. 实用癌症杂志, 2016, 31(10): 1684-1690.</mixed-citation></ref><ref id="hanspub.28547-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Stoodley, P.W., Richards, D.A., Boyd, A., et al. (2013) Altered Left Ventricular Longitudinal Diastolic Function Correlates with Reduced Systolic Function Immediately after Anthracycline Chemotherapy. European Heart Journal—Cardiovascular Imaging, 14, 228-234. &lt;br&gt;https://doi.org/10.1093/ehjci/jes139</mixed-citation></ref><ref id="hanspub.28547-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">贺飞, 薄明明, 梁锌, 彭黎黎, 陈岷, 李国辉. 蒽环类药物致乳腺癌患者急性心脏毒性的发生及影响因素的回顾性研究[J]. 中国药学杂志, 2017, 52(12): 1089-1092.</mixed-citation></ref><ref id="hanspub.28547-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">齐宇新, 刘姣, 何颖娜, 任艳青. 乳腺癌术后蒽环类化疗药物致心脏损害的早期监测分析[J]. 中国药房, 2017, 28(17): 2356-2359.</mixed-citation></ref><ref id="hanspub.28547-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Planchard, D., Yokoi, T., McCleod, M.J., et al. (2016) A Phase Ⅲ Study of Durvalumab (MEDI4736) with or without Tremelimumab for Previously Treated Patients with Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. Clinical Lung Cancer, 17, 232-236. &lt;br&gt;https://doi.org/10.1016/j.cllc.2016.03.003</mixed-citation></ref><ref id="hanspub.28547-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kaufman, H.L., Russell, J., Hamid, O., et al. (2016) Avelumab in Patients with Chemotherapy-Refractory Metastatic Merkel Cell Carcinoma: a Multicentre, Single-Group, Open-Label, Phase 2 Trial. Lancet Oncology, 17, 1374-1385.  
&lt;br&gt;https://doi.org/10.1016/S1470-2045(16)30364-3</mixed-citation></ref><ref id="hanspub.28547-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">周明岩, 孙一欣, 那子悦, 温欣, 程文. 超声心动图对化疗药所致心脏毒性的评估[J]. 肿瘤学杂志, 2018, 24(6): 606-610.</mixed-citation></ref><ref id="hanspub.28547-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kremer, L.C., vail Dallen, E.C., Offringa, M., et al. (2001) Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow up Study. Journal of Clinical Oncology, 19, 191-196.  
&lt;br&gt;https://doi.org/10.1200/JCO.2001.19.1.191</mixed-citation></ref><ref id="hanspub.28547-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hsiao, J.F., Koshino, Y., Bonnichsen, C.R., et al. (2013) Speckle Racking Echocardiography in Acute Myocarditis. International Journal of Cardiovascular Imaging, 29, 275-284. &lt;br&gt;https://doi.org/10.1007/s10554-012-0085-6</mixed-citation></ref></ref-list></back></article>